This study aimed to evaluate the clinical analgesic efficacy and identify the molecular targets of XGDP for treating primary\ndysmenorrhea (PD) by a network pharmacology approach. Analysis of pain disappearance rate of XGDP in PD treatment was\nconducted based on data from phase II and III randomized, double-blind, double-simulation, and positive parallel controlled\nclinical trials. The bioactive compounds were obtained by the absorption, distribution, metabolism, and excretion processes with\noral bioavailability (OB) and drug-likeness (DL) evaluation. Subsequently, target prediction, pathway identification, and network\nconstructionwere employed to clarify the mechanisms of the analgesic effect of XGDP on PD.Thepain disappearance rates in phase\nII and III clinical trials of XGDP in PD treatment were 62.5% and 55.8%, respectively, yielding a significant difference (
Loading....